Insulin Receptor 1142-1153

CAS No. 141171-54-2

Insulin Receptor 1142-1153 ( [pTyr1146][pTyr1150][pTyr1151]Insulin Receptor 1142-1153 )

Catalog No. M29958 CAS No. 141171-54-2

[pTyr1146][pTyr1150][pTyr1151]Insulin Receptor (1142-1153) binds to insulin and can be used as insulin receptor tyrosine kinase substrates.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote

Biological Information

  • Product Name
    Insulin Receptor 1142-1153
  • Note
    Research use only, not for human use.
  • Brief Description
    [pTyr1146][pTyr1150][pTyr1151]Insulin Receptor (1142-1153) binds to insulin and can be used as insulin receptor tyrosine kinase substrates.
  • Description
    [pTyr1146][pTyr1150][pTyr1151]Insulin Receptor (1142-1153) binds to insulin and can be used as insulin receptor tyrosine kinase substrates.
  • Synonyms
    [pTyr1146][pTyr1150][pTyr1151]Insulin Receptor 1142-1153
  • Pathway
    Tyrosine Kinase
  • Target
    Insulin Receptor
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    141171-54-2
  • Formula Weight
    1862.7
  • Molecular Formula
    C72H110N19O33P3
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

Shintani T, et al. The R3 receptor-like protein tyrosine phosphatase subfamily inhibits insulin signalling by dephosphorylating the insulin receptor at specific sites. J Biochem. 2015 Sep;158(3):235-43.
molnova catalog
related products
  • Insulin degludec

    Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by type 1 and type 2 dabetes. Insulin degludec shows binding efficiency with an IC50 value of 19.59 nM/L for insulin receptor. Insulin degludec can be used for the research of type 1 and type 2 diabetes.

  • [D-Ala2]-GIP (human)

    Highly potent GIP receptor agonist (EC50 = 630 ± 119 pM). Displays equivalent cAMP stimulating properties and improved resistance to enzymatic degradation compared to native GIP in cells expressing wild type GIP receptor. Improves glucose tolerance, insulin release and cognitive function in various animal models of obesity and diabetes. Displays neuroprotective effects in an MPTP model of PD.

  • GIP (1-30) amide (Hu...

    GIP (1-30) amide (Human) is an insulin-dependent glucose-dependent polypeptide.The sugar-dependent insulin polypeptide (GIP) is an insulin secreting hormone, which can stimulate the secretion of insulin and reduce the occurrence of postpranal-glycemic diseases.